Table 3.

Association of ODC G316A genotype and adenoma recurrence in all subjects and following stratification by aspirin treatment

ODC genotypeAll subjects
Aspirin treatment
Placebo
Aspirin
Recurrence/total (%)RR (95% CI)*Recurrence/total (%)RR (95% CI)*Recurrence/total (%)RR (95% CI)*
All adenomas
    GG82/310 (26.5)1.00 (reference)44/156 (28.2)1.00 (reference)38/154 (24.7)0.88 (0.62-1.26)
    GA52/207 (25.1)0.92 (0.70-1.21)28/111 (25.2)0.85 (0.56-1.23)24/96 (25.0)0.88 (0.58-1.32)
    AA3/29 (10.3)0.43 (0.16-1.15)2/13 (15.4)0.56 (0.20-1.60)1/16 (6.25)0.24 (0.03-1.71)
Advanced lesions
    GG37/310 (11.9)1.00 (reference)22/156 (14.1)1.00 (reference)15/154 (9.7)0.69 (0.33-1.32)
    GA31/207 (15.0)1.18 (0.78-1.81)18/111 (19.4)1.02 (0.60-1.73)13/96 (13.5)0.93 (0.50-1.72)
    AA2/29 (6.9)0.62 (0.15-2.56)1/13 (7.7)0.55 (0.07-4.17)1/16 (6.3)0.49 (0.06-4.14)
  • * RR and 95% CIs adjusted for sex and interval between entry and follow-up colonoscopy.

  • Advanced lesions were defined as colorectal adenomas with villous or tubulovillous features, size ≥1 cm, severe dysplasia, or colorectal carcinoma.